Der Gynäkologe

, Volume 51, Issue 4, pp 326–328 | Cite as

Kommentar zu: Immundiagnostik und -therapie des habituellen Aborts

Blick zurück

Comments on: Immunodiagnostics and immunotherapy of habitual abortion



R.-J. Kuon gibt an, dass kein Interessenkonflikt besteht.


  1. 1.
    ESHRE Early Pregnancy Guideline Development Group (2017) ESHRE Guideline on the management of recurrent pregnancy loss, S 1–154Google Scholar
  2. 2.
    ACOG (2002) ACOG practice bulletin. Management of recurrent pregnancy loss. Number 24, February 2001. (Replaces Technical Bulletin Number 212, September 1995). American College of Obstetricians and Gynecologists. Int J Gynecol Obstet 78:179–190CrossRefGoogle Scholar
  3. 3.
    Bouteiller P, Rodriguez A‑M, Mallet V et al (2011) Placental expression of HLA class I genes. Am J Reprod Immunol 35:216–225CrossRefGoogle Scholar
  4. 4.
    Dahl M, Hviid TVF (2012) Human leucocyte antigen class Ib molecules in pregnancy success and early pregnancy loss. Hum Reprod Update 18:92–109CrossRefPubMedGoogle Scholar
  5. 5.
    Fernandez N, Cooper J, Sprinks M et al (1999) A critical review of the role of the major histocompatibility complex in fertilization, preimplantation development and feto-maternal interactions. Hum Reprod Update 5:234–248CrossRefPubMedGoogle Scholar
  6. 6.
    Guideline no 17 London RCOG G‑T (2011) The Investigation and Treatment of Couples with Recurrent First-trimester and Second-trimester Miscarriage. April 2011Google Scholar
  7. 7.
    Hammer A, Hutter H, Blaschitz A et al (2011) Amnion epithelial cells, in contrast to trophoblast cells, express all classical HLA class I molecules together with HLA-G. Am J Reprod Immunol 37:161–171CrossRefGoogle Scholar
  8. 8.
    Hviid MM, Macklon N (2017) Immune modulation treatments-where is the evidence? Fertil Steril 107:1284–1293CrossRefPubMedGoogle Scholar
  9. 9.
    Kuon RJ, Vomstein K, Weber M et al (2017) The „killer cell story“ in recurrent miscarriage: association between activated peripheral lymphocytes and uterine natural killer cells. J Reprod Immunol 119:9–14CrossRefPubMedGoogle Scholar
  10. 10.
    Laird SM (2003) A review of immune cells and molecules in women with recurrent miscarriage. Hum Reprod Update 9:163–174CrossRefPubMedGoogle Scholar
  11. 11.
    Middleton D, Curran M, Maxwell L (2002) Natural killer cells and their receptors. Transpl Immunol 10:147–164CrossRefPubMedGoogle Scholar
  12. 12.
    Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306CrossRefPubMedGoogle Scholar
  13. 13.
    Seshadri S, Sunkara SK (2014) Natural killer cells in female infertility and recurrent miscarriage: a systematic review and meta-analysis. Hum Reprod Update 20:429–438CrossRefPubMedGoogle Scholar
  14. 14.
    Thielens A, Vivier E, Romagné F (2012) NK cell MHC class I specific receptors (KIR): from biology to clinical intervention. Curr Opin Immunol 24:239–245CrossRefPubMedGoogle Scholar
  15. 15.
    Toth B, Würfel W, Bohlmann MK et al (2015) Recurrent miscarriage: diagnostic and therapeutic procedures. Guideline of the DGGG (S1-level, AWMF registry no. 015/050, december 2013). Geburtshilfe Frauenheilkd 75:1117–1129CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Wilson WA, Gharavi AE, Koike T et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshop. Arthritis Rheum 42:1309–1311CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Abteilung für Gynäkologische Endokrinologie und FertilitätsstörungenHeidelbergDeutschland

Personalised recommendations